ReviewCurrent opinion in rheumatology2018
An update on autoantibodies in scleroderma.
Review in Current opinion in rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Mapping of the Antinuclear Autoantibodies in Sudanese patients infected with Human Immunodeficiency Virus after HAART receiving: A cross-sectional study.Scientific reports · 2025Article
- Comparative Evaluation of Bleomycin- and Collagen-V-Induced Models of Systemic Sclerosis: Insights into Fibrosis and Autoimmunity for Translational Research.International journal of molecular sciences · 2025Article
- Paraneoplastic scleroderma: a patient with a history of breast cancer presenting with sclerodactyly and Raynaud's phenomenon.BMJ case reports · 2025Article
- IP-to-MS: An Unbiased Workflow for Antigen Profiling.Journal of proteome research · 2025Article
- Prevalence of Autoimmune Diseases in Patients Treated With Immune Checkpoint Inhibitors: An Epidemiological Study Using A Global Network of Health Care Organizations.ACR open rheumatology · 2025Article
- Significance of Systemic Scleroderma-Specific Autoantibodies in Idiopathic Interstitial Pneumonia.Cureus · 2024Article
- Immunogenetics of Systemic Sclerosis.Genes · 2024Review
- Immune Checkpoint Inhibitor-Associated Systemic Sclerosis in the Treatment of a Small Cell Lung Cancer Patient with Durvalumab: A Case Report.Clinical, cosmetic and investigational dermatology · 2024Article
- Pathogenesis of autoimmune disease.Nature reviews. Nephrology · 2023Review
- Systemic sclerosis following COVID-19 infection with recurrent corticosteroid-induced scleroderma renal crisis.BMJ case reports · 2023Article
- Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The Past, Present, and Future in Antinuclear Antibodies (ANA).Diagnostics (Basel, Switzerland) · 2022Review
- Transfer of PBMC From SSc Patients Induces Autoantibodies and Systemic Inflammation in Rag2-/-/IL2rg-/- Mice.Frontiers in immunology · 2021Article
- Chromatin accessibility landscapes of skin cells in systemic sclerosis nominate dendritic cells in disease pathogenesis.Nature communications · 2020Article
- Biomarkers in systemic sclerosis.Current opinion in rheumatology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewNew research continues to provide important insights into the utility of antibody specificities. This review provides an update of recent findings, and the important insights they provide into disease mechanism. RECENT
findingsA growing number of autoantibodies have been discovered in scleroderma patients with unique clinical associations. A subgroup of these antibodies may have functional consequences and contribute to disease pathogenesis, driving the vascular and fibrotic phenotype. Recent research into the relationship between malignancy and scleroderma onset provides important new insights into disease mechanism, and highlights the utility of autoantibodies as unique research probes. SUMMARY: Continued advances in the study of scleroderma antibody specificities has led to important insights into disease pathogenesis and clinical subgrouping. These advances include newly described specificities, functional antibodies and an emerging understanding of the cancer-scleroderma relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.